| Human skin penetration of silver nanoparticles through intact and damaged skin FF Larese, F D’Agostin, M Crosera, G Adami, N Renzi, M Bovenzi, ... Toxicology 255 (1-2), 33-37, 2009 | 550 | 2009 |
| Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study H Gacaferi, GS Collaborative, COVIDSurg Collaborative Anaesthesia 76 (6), 2021 | 548* | 2021 |
| Nanoparticle dermal absorption and toxicity: a review of the literature M Crosera, M Bovenzi, G Maina, G Adami, C Zanette, C Florio, ... International archives of occupational and environmental health 82, 1043-1055, 2009 | 389 | 2009 |
| Recent life events and obsessive–compulsive disorder (OCD): the role of pregnancy/delivery G Maina, U Albert, F Bogetto, P Vaschetto, L Ravizza Psychiatry research 89 (1), 49-58, 1999 | 313 | 1999 |
| Gender-related clinical differences in obsessive-compulsive disorder F Bogetto, S Venturello, U Albert, G Maina, L Ravizza European psychiatry 14 (8), 434-441, 1999 | 304 | 1999 |
| Predictors of drug treatment response in obsessive-compulsive disorder. L Ravizza, G Barzega, S Bellino, F Bogetto, G Maina The Journal of clinical psychiatry 56 (8), 368-373, 1995 | 281 | 1995 |
| Psychiatric comorbidity in patients with burning mouth syndrome F Bogetto, G Maina, G Ferro, M Carbone, S Gandolfo Psychosomatic Medicine 60 (3), 378-385, 1998 | 240 | 1998 |
| Fibromyalgia syndrome and depressive symptoms: comorbidity and clinical correlates A Aguglia, V Salvi, G Maina, I Rossetto, E Aguglia Journal of affective disorders 128 (3), 262-266, 2011 | 226 | 2011 |
| Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study G Maina, A Vitalucci, S Gandolfo, F Bogetto Journal of Clinical Psychiatry 63 (1), 38-43, 2002 | 214 | 2002 |
| Family accommodation in obsessive–compulsive disorder: Relation to symptom dimensions, clinical and family characteristics U Albert, F Bogetto, G Maina, P Saracco, C Brunatto, D Mataix-Cols Psychiatry research 179 (2), 204-211, 2010 | 200 | 2010 |
| What happened to patients with obsessive compulsive disorder during the COVID-19 pandemic? A multicentre report from tertiary clinics in northern Italy B Benatti, U Albert, G Maina, A Fiorillo, L Celebre, N Girone, N Fineberg, ... Frontiers in psychiatry 11, 566245, 2020 | 187 | 2020 |
| Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder G Maina, V Salvi, A Vitalucci, V D'Ambrosio, F Bogetto Journal of Affective Disorders 110 (1-2), 149-155, 2008 | 184 | 2008 |
| Drug delivery nanoparticles in skin cancers C Dianzani, GP Zara, G Maina, P Pettazzoni, S Pizzimenti, F Rossi, ... BioMed research international 2014 (1), 895986, 2014 | 183 | 2014 |
| Surface characterization of silver-doped bioactive glass E Vernè, S Di Nunzio, M Bosetti, P Appendino, CV Brovarone, G Maina, ... Biomaterials 26 (25), 5111-5119, 2005 | 180 | 2005 |
| Human skin penetration of gold nanoparticles through intact and damaged skin F Larese Filon, M Crosera, G Adami, M Bovenzi, F Rossi, G Maina Nanotoxicology 5 (4), 493-501, 2011 | 176* | 2011 |
| Peripheral whole blood microRNA alterations in major depression and bipolar disorder E Maffioletti, A Cattaneo, G Rosso, G Maina, C Maj, M Gennarelli, ... Journal of affective disorders 200, 250-258, 2016 | 168 | 2016 |
| Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression P Monteleone, M Bifulco, G Maina, A Tortorella, P Gazzerro, MC Proto, ... Pharmacological research 61 (5), 400-404, 2010 | 165 | 2010 |
| Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study U Albert, E Aguglia, G Maina, F Bogetto Journal of Clinical Psychiatry 63 (11), 1004-1009, 2002 | 159 | 2002 |
| Impact of anxiety disorder comorbidity on quality of life in euthymic bipolar disorder patients: differences between bipolar I and II subtypes U Albert, G Rosso, G Maina, F Bogetto Journal of affective disorders 105 (1-3), 297-303, 2008 | 154 | 2008 |
| Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). L Ravizza, G Barzega, S Bellino, F Bogetto, G Maina Psychopharmacology Bulletin 32 (1), 167-173, 1996 | 153 | 1996 |
